Plinabulin – NSCLC


Plinabulin is being evaluated to be combined with docetaxel for treatment of advanced non-small cell lung cancer (NSCLC) and is currently in a Phase 3 global multi-center clinical trial. This trial is being conducted in the U.S., China and Australia for Plinabulin in combination with docetaxel in patients with advanced NSCLC with measurable lung lesions, or Study 103.

Clinical Trial

For details of this trial, please visit the below website.

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3)